Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results
Rhea-AI Summary
Zepp Health (NYSE: ZEPP) reported unaudited second-quarter 2026 revenue of US$63.5 million, up 6.9% year over year, with gross margin rising to 37.4%, a 1.2‑percentage‑point increase driven mainly by a richer product mix. GAAP net loss attributable to Zepp widened to US$11.3 million from US$7.7 million as foreign‑exchange headwinds and higher R&D and marketing spending more than offset margin gains.
Cash and restricted cash reached US$106.3 million at June 30, 2026, up from US$95.3 million a year earlier, supported by improved working‑capital management. Inventory fell versus the prior year, and the company converted US$13.3 million of short‑term debt into long‑term obligations. Management guided third‑quarter 2026 net revenue to US$68–73 million, below the prior year’s US$75.8 million high base. Zepp expanded multiple product families, plans Bip price increases from January 2027, announced director Alain Lam’s resignation effective September 1, 2026, and noted the continuation of its up‑to‑US$20 million share repurchase program.
Positive
- Revenue US$63.5 million, up 6.9% year over year in Q2 2026
- Gross margin 37.4%, up 1.2 percentage points year over year
- Cash and restricted cash US$106.3 million, higher than both year-ago and Q1 2026
- Operating expenses declined quarter over quarter versus Q1 2026
- US$13.3 million of short-term debt converted to long-term, extending maturities
- Inventory US$62.4 million, down from US$79.9 million a year earlier
Negative
- GAAP net loss US$11.3 million, wider than US$7.7 million a year earlier
- GAAP operating loss US$12.3 million, higher than US$6.1 million in Q2 2025
- Selling and marketing expenses US$18.3 million, up from US$12.1 million year over year
- Total operating expenses up US$8.4 million year over year to US$36.0 million GAAP
- First-half 2026 net loss US$31.0 million, larger than US$27.5 million in 2025
- Q3 2026 revenue guidance US$68–73 million is below last year’s US$75.8 million
News Explained
Zepp Health has an authorized share-repurchase program running through
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Q1 earnings | Positive | -28.6% | Revenue growth and margin improvement accompanied by substantial share-price decline |
| Mar 15 | Q4 earnings | Positive | -22.1% | Strong quarterly revenue and narrowed losses accompanied by a sharp decline |
| Nov 04 | Q3 earnings | Positive | -6.0% | Record quarterly growth and improved profitability accompanied by a decline |
| Aug 03 | Q2 earnings | Positive | +34.0% | Strong revenue growth and improved losses accompanied by a 34% gain |
| May 19 | Q1 earnings | Neutral | -6.3% | Mixed quarter with product growth and net loss accompanied by decline |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ZEPP's tag-matched earnings announcements produced negative reactions in four of five observed events, including three declines despite positive operating updates.
Key Terms
gaap financial
adjusted operating expenses financial
foreign-exchange headwinds financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Second Quarter of 2026 Financial and Operating Highlights:
- Revenue reached
US , representing year-over-year growth of$63.5 million 6.9% . - Gross margin was
37.4% , an increase of 1.2 percentage points from the second quarter of 2025. The improvement was primarily driven by a more favorable product mix and growing contribution from higher-value products, partially offset by higher memory and other component costs. - Net loss attributable to Zepp was
US , compared with$11.3 million US in the same period of 2025. The benefits of higher revenue and improved gross margin were offset by foreign-exchange headwinds and increased investment in research and development, marketing and brand building.$7.7 million - As of June 30, 2026, cash and cash equivalents and restricted cash totaled
US , compared with$106.3 million US a year earlier and$95.3 million US as of March 31, 2026, primarily reflecting improved working-capital management.$103.2 million - During the quarter, the Company launched new products or expanded its portfolio across multiple major product families, including professional running, Hybrid Training, entry-level smartwatches and screen-free fitness and health wearables.
Management Comments:
Wayne Huang, Chairman and Chief Executive Officer of Zepp Health, commented, "Our growth in the second quarter was measured rather than explosive. More importantly, the quality of our growth and the structure of our product portfolio continued to improve. Even before several new products had completed their production ramp and channel deployment, and despite supply continuing to constrain certain high-demand areas, we returned to year-over-year revenue growth and improved gross margin by 1.2 percentage points.
Several product families provide clear evidence of this structural progress. At
Active series has established a
Balance is beginning to demonstrate how our long-term investment in Hybrid Training can translate into higher-value product demand. Compared with Balance 2 at a
These positive indicators have not yet translated into their full revenue potential. T-Rex currently represents a story of sustained higher-end mix rather than rapid unit growth. Balance has only begun to establish growth momentum. Bip and Helio Strap were constrained by supply during the second quarter, while Cheetah and Helio Strap Pro remain at earlier stages of professional credibility and market development. The financial contribution of these product families is therefore developing at different speeds.
Bip supply has now recovered. Seventeen months after its launch, demand for Bip 6 remains very strong following the restoration of supply, while Bip Max has established a meaningful higher price tier within the family. Supported by sustained consumer demand, a more complete product structure, and the continued software evolution enabled by our in-house processor platform and Zepp OS, we are announcing today that we will increase prices across the entire Bip family beginning in January 2027. Our objective is to improve pricing discipline and unit economics while preserving a compelling consumer value proposition over a longer product lifecycle.
Demand for Helio Strap also exceeded available supply during the second quarter. We expect supply to recover partially during the third quarter and to be fully restored during the fourth quarter. As availability improves, we expect Helio Strap to make a more meaningful contribution to our screen-free fitness, training and recovery ecosystem."
Leon Deng, Chief Financial Officer of Zepp Health, commented, "The year-over-year improvement in gross margin, despite higher memory and other component costs, demonstrates that the shift in our product mix is beginning to yield tangible financial benefits. At the same time, foreign-exchange headwinds and continued investment in research and development, marketing and brand building affected profitability during the second quarter.
We will remain disciplined in managing our expenses and cash, while working to expand the contribution of higher-value products, restore supply where demand remains strong, and progressively convert product-mix improvements into stronger revenue growth, healthier unit economics and operating leverage. With our cash and cash equivalents and restricted cash balance of
Third Quarter of 2026 Outlook:
Based on the information currently available, management expects third-quarter 2026 net revenues to be between US
Product mix and consumer demand continued to improve during July and August. However, normal production ramp, supply-recovery and channel-deployment cycles mean that these developments will not be fully reflected in reported revenue immediately. The Company's third-quarter guidance incorporates this timing.
Second Quarter of 2026 Financial Results
Revenues
Revenues for the second quarter of 2026 reached
Gross Margin
Gross margin in the second quarter of 2026 was
Research and Development Expenses
Research and development expenses in the second quarter of 2026 were
Selling and Marketing Expenses
Selling and marketing expenses in the second quarter of 2026 were
General and Administrative Expenses
General and administrative expenses were
Operating Expenses
GAAP and adjusted operating expenses[1] for the second quarter of 2026 were
[1] Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Please refer to the section titled "Reconciliation of GAAP and non-GAAP results" at the end of this press release. |
Operating Income/(Loss)
GAAP and adjusted operating results[2] were loss of
Net Income/(Loss)
GAAP and adjusted net loss[3] attributable to Zepp for the second quarter of 2026 was
[2] Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release. |
[3] Adjusted net income/(loss) attributable to Zepp Health Corporation represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release. |
Liquidity and Capital Resources
As of June 30, 2026, cash and cash equivalents and restricted cash were
The Company recorded inventory of
Long-term and short-term debt levels increased by
Resignation of Director
The Company announces that Mr. Alain Lam has tendered his resignation as a director of the Company, with effect from September 1, 2026, in order to devote more time to his responsibilities at Xiaomi. Mr. Lam has confirmed that (i) he has no disagreement with the board of directors of the Company (the "Board") and (ii) there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company. Xiaomi will remain as a significant shareholder of the Company. The Company appreciates Mr. Lam's longstanding support and contributions and thanks him for his service on the Board.
Share Repurchase Program Update
The Company announced in its third quarter 2021 earnings release that the board had authorized a share repurchase program of up to
Outlook
For the third quarter of 2026, the Company's management currently expects net revenues to be between US
This outlook is based on current market conditions and reflects the Company's current and preliminary estimates of market, operating conditions and customer demand, which are all subject to change.
Conference Call
The Company's management team will hold a conference call at 9:30 p.m. Eastern Time on Tuesday, September 1, 2026 to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:
US (Toll Free): | +1-888-346-8982 |
International: | +1-412-902-4272 |
Mainland | 400-120-1203 |
800-905-945 |
Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation".
Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.
A telephone replay will be available one hour after the call until September 8, 2026 by dialing:
US Toll Free: | +1-855-669-9658 |
International: | +1-412-317-0088 |
Replay Passcode: | 5342073 |
About Zepp Health Corporation
Zepp Health Corporation (NYSE: ZEPP) is a global leader in smart wearables and health technology, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes Zepp OS, AI chips, biometric sensors, and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units and served more than 53 million users, and its products are available in more than 150 countries and regions. Zepp Health has team members and offices across the globe, especially in Europe and the United States.
Use of Non-GAAP Measures
We use adjusted net income/(loss), a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted EBIT represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/expense, and (vii) interest income and interest expense. Adjusted net income/(loss) attributable to Zepp Health Corporation is a non-GAAP measure, which excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted net income/(loss) per share and per ADS attributable to Zepp Health Corporation.
We believe that adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income/(loss) and net income/(loss) attributable to Zepp Health Corporation. We believe adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.
Adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income/(loss), basic and diluted net income/(loss) per share and per ADS attributable to Zepp Health Corporation or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted EBIT and adjusted net income/(loss) attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the recognition of the Company's Amazfit-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions around the globe. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com
Piacente Financial Communications
Tel: +86-10-6508-0677
Email: zepp@tpg-ir.com
Zepp Health Corporation | ||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
(Amounts in thousands of | ||||
except for number of shares and per share data, or otherwise noted) | ||||
As of December 31, | As of June 30, | |||
2025 | 2026 | |||
US$ | US$ | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | 57,046 | 69,661 | ||
Restricted cash | 55,887 | 36,608 | ||
Accounts receivable, net | 66,908 | 75,537 | ||
Amounts due from related parties | 6,665 | 7,051 | ||
Inventories, net | 72,756 | 62,434 | ||
Prepaid expenses and other current assets | 34,263 | 31,221 | ||
Total current assets | 293,525 | 282,512 | ||
Property, plant and equipment, net | 5,662 | 5,449 | ||
Intangible asset, net | 13,611 | 12,808 | ||
Goodwill | 9,581 | 9,581 | ||
Long-term investments | 220,047 | 227,821 | ||
Deferred tax assets | 15,743 | 16,024 | ||
Amount due from related parties, non-current | 991 | - | ||
Other non-current assets | 3,718 | 3,346 | ||
Operating lease right-of-use assets | 1,958 | 2,128 | ||
Total assets | 564,836 | 559,669 | ||
Zepp Health Corporation | ||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED | ||||
(Amounts in thousands of | ||||
except for number of shares and per share data, or otherwise noted) | ||||
As of December 31, | As of June 30, | |||
2025 | 2026 | |||
US$ | US$ | |||
Liabilities | ||||
Current liabilities: | ||||
Accounts payable | 80,768 | 87,979 | ||
Advance from customers | 76 | 56 | ||
Amounts due to related parties | 654 | 396 | ||
Accrued expenses and other current liabilities | 37,527 | 37,182 | ||
Income tax payables | 366 | 249 | ||
Notes payable | 111,725 | 111,672 | ||
Short-term bank borrowings | 55,728 | 76,842 | ||
Total current liabilities | 286,844 | 314,376 | ||
Deferred tax liabilities | 2,673 | 2,754 | ||
Long-term borrowings | 59,475 | 56,397 | ||
Other non-current liabilities | 209 | 108 | ||
Non-current operating lease liabilities | 1,102 | 1,066 | ||
Total liabilities | 350,303 | 374,701 | ||
Zepp Health Corporation | ||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED | ||||
(Amounts in thousands of | ||||
except for number of shares and per share data, or otherwise noted) | ||||
As of December 31, | As of June 30, | |||
2025 | 2026 | |||
US$ | US$ | |||
Equity | ||||
Ordinary shares | 26 | 26 | ||
Additional paid-in capital | 280,676 | 282,326 | ||
Treasury stock | (16,153) | (17,568) | ||
Accumulated retained earnings/(loss) | (11,450) | (42,423) | ||
Accumulated other comprehensive loss | (38,566) | (37,393) | ||
Total equity | 214,533 | 184,968 | ||
Total liabilities and equity | 564,836 | 559,669 | ||
Zepp Health Corporation | |||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
(Amounts in thousands of | |||||
except for number of shares and per share data, or otherwise noted) | |||||
For the Three Months Ended June 30, | |||||
2025 | 2026 | ||||
US$ | US$ | ||||
Revenues | 59,406 | 63,525 | |||
Cost of revenues | (37,915) | (39,797) | |||
Gross profit | 21,491 | 23,728 | |||
Operating expenses: | |||||
Selling and marketing | (12,050) | (18,288) | |||
General and administrative | (4,384) | (6,200) | |||
Research and development | (11,157) | (11,545) | |||
Total operating expenses | (27,591) | (36,033) | |||
Operating loss | (6,100) | (12,305) | |||
Other income and expenses: | |||||
Interest income | 295 | 465 | |||
Interest expense | (1,245) | (1,679) | |||
Gain from fair value change of long-term investments | 3 | 3,040 | |||
Other income/(expense), net | 56 | (14) | |||
Loss before income tax and loss from equity method investments | (6,991) | (10,493) | |||
Income tax expenses | (242) | (114) | |||
Loss before loss from equity method investments | (7,233) | (10,607) | |||
Net loss from equity method investments | (507) | (723) | |||
Net loss attributable to Zepp Health Corporation | (7,740) | (11,330) | |||
Basic and diluted net loss per share attributable to Zepp Health | (0.03) | (0.04) | |||
Basic and diluted net loss per ADS (16 ordinary shares equal to | (0.49) | (0.72) | |||
Weighted average number of shares used in computing basic and | 253,536,783 | 253,356,305 | |||
Zepp Health Corporation | |||||
Reconciliation of GAAP and Non-GAAP Results | |||||
(Amounts in thousands of | |||||
except for number of shares and per share data, or otherwise noted) | |||||
For the Three Months Ended June 30, | |||||
2025 | 2026 | ||||
US$ | US$ | ||||
Total operating expenses | (27,591) | (36,033) | |||
Share-based compensation expenses | 482 | 715 | |||
Amortization of intangible assets resulting from acquisitions | 711 | 494 | |||
Total adjusted operating expenses | (26,398) | (34,824) | |||
Operating loss | (6,100) | (12,305) | |||
Share-based compensation expenses | 482 | 715 | |||
Amortization of intangible assets resulting from acquisitions | 711 | 494 | |||
Adjusted operating loss | (4,907) | (11,096) | |||
Net loss | (7,740) | (11,330) | |||
Share-based compensation expenses | 482 | 715 | |||
Amortization of intangible assets resulting from acquisitions | 711 | 494 | |||
Interest income | (295) | (465) | |||
Interest expense | 1,245 | 1,679 | |||
Gain from fair value change of long-term investments | (3) | (3,040) | |||
Income tax expenses | 242 | 114 | |||
Loss from equity method investments | 507 | 723 | |||
Adjusted EBIT[4] | (4,851) | (11,110) | |||
Net loss attributable to Zepp Health Corporation | (7,740) | (11,330) | |||
Share-based compensation expenses | 482 | 715 | |||
Amortization of intangible assets resulting from acquisitions | 711 | 494 | |||
Gain from fair value change of long-term investments | (3) | (3,040) | |||
Tax effects on non-GAAP adjustments | (116) | (84) | |||
Loss from equity method investments | 507 | 723 | |||
Adjusted net loss attributable to Zepp Health Corporation | (6,159) | (12,522) | |||
Adjusted basic and diluted net loss per share attributable | (0.02) | (0.05) | |||
Adjusted basic and diluted net loss per ADS (16 ordinary | (0.39) | (0.79) | |||
Weighted average number of shares used in computing | 253,536,783 | 253,356,305 | |||
Share-based compensation expenses included are as follows: | |||||
Selling and marketing | 3 | 81 | |||
General and administrative | 289 | 352 | |||
Research and development | 190 | 282 | |||
Total | 482 | 715 | |||
[4] Adjusted EBIT is a non-GAAP financial measure, which is defined as net loss, excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/ expense, and (vii) interest income and interest expense. |
[5] Adjusted diluted net income/(loss) is the abbreviation of adjusted net (loss)/income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investments, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted basic and diluted net loss per ADS attributable to Zepp Health Corporation. |
Zepp Health Corporation | |||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
(Amounts in thousands of | |||||
except for number of shares and per share data, or otherwise noted) | |||||
For the Six Months Ended June 30, | |||||
2025 | 2026 | ||||
US$ | US$ | ||||
Revenues | 97,943 | 115,072 | |||
Cost of revenues | (62,091) | (71,907) | |||
Gross profit | 35,852 | 43,165 | |||
Operating expenses: | |||||
Selling and marketing | (25,891) | (34,928) | |||
General and administrative | (10,902) | (13,555) | |||
Research and development | (23,534) | (24,679) | |||
Total operating expenses | (60,327) | (73,162) | |||
Operating loss | (24,475) | (29,997) | |||
Other income and expenses: | |||||
Interest income | 876 | 796 | |||
Interest expense | (2,603) | (3,333) | |||
(Loss)/gain from fair value change of long-term investments | (122) | 3,117 | |||
Other income/(expense), net | 60 | (66) | |||
Loss before income tax and loss from equity method investments | (26,264) | (29,483) | |||
Income tax expenses | (352) | (328) | |||
Loss before loss from equity method investments | (26,616) | (29,811) | |||
Net loss from equity method investments | (865) | (1,162) | |||
Net loss | (27,481) | (30,973) | |||
Less: Net loss attributable to noncontrolling interest | - | - | |||
Net loss attributable to Zepp Health Corporation | (27,481) | (30,973) | |||
Basic and diluted net loss per share attributable to Zepp Health | (0.11) | (0.12) | |||
Basic and diluted net loss per ADS (16 ordinary shares equal to | (1.72) | (1.95) | |||
Weighted average number of shares used in computing basic | 254,965,539 | 253,533,249 | |||
Zepp Health Corporation | |||||
Reconciliation of GAAP and Non-GAAP Results | |||||
(Amounts in thousands of | |||||
except for number of shares and per share data, or otherwise noted) | |||||
For the Six Months Ended June 30, | |||||
2025 | 2026 | ||||
US$ | US$ | ||||
Total operating expenses | (60,327) | (73,162) | |||
Share-based compensation expenses | 1,071 | 1,650 | |||
Amortization of intangible assets resulting from acquisitions | 1,346 | 984 | |||
Total adjusted operating expenses | (57,910) | (70,528) | |||
Operating loss | (24,475) | (29,997) | |||
Share-based compensation expenses | 1,071 | 1,650 | |||
Amortization of intangible assets resulting from acquisitions | 1,346 | 984 | |||
Adjusted operating loss | (22,058) | (27,363) | |||
Net loss | (27,481) | (30,973) | |||
Share-based compensation expenses | 1,071 | 1,650 | |||
Amortization of intangible assets resulting from acquisitions | 1,346 | 984 | |||
Interest income | (876) | (796) | |||
Interest expense | 2,603 | 3,333 | |||
Loss/(gain) from fair value change of long-term investments | 122 | (3,117) | |||
Income tax expenses | 352 | 328 | |||
Loss from equity method investments | 865 | 1,162 | |||
Adjusted EBIT | (21,998) | (27,429) | |||
Net loss attributable to Zepp Health Corporation | (27,481) | (30,973) | |||
Share-based compensation expenses | 1,071 | 1,650 | |||
Amortization of intangible assets resulting from acquisitions | 1,346 | 984 | |||
Loss/(gain) from fair value change of long-term investments | 122 | (3,117) | |||
Tax effects on non-GAAP adjustments | (219) | (167) | |||
Loss from equity method investments | 865 | 1,162 | |||
Adjusted net loss attributable to Zepp Health Corporation | (24,296) | (30,461) | |||
Adjusted basic and diluted net loss per share attributable | (0.10) | (0.12) | |||
Adjusted basic and diluted net loss per ADS (16 ordinary | (1.52) | (1.92) | |||
Weighted average number of shares used in computing | 254,965,539 | 253,533,249 | |||
Share-based compensation expenses included are follows: | |||||
Selling and marketing | 45 | 277 | |||
General and administrative | 575 | 352 | |||
Research and development | 451 | 1,021 | |||
Total | 1,071 | 1,650 | |||
View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-second-quarter-of-2026-unaudited-financial-results-302866933.html
SOURCE Zepp Health Corp.